Drug Manufacturers - Specialty & Generic
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
|
RDHL
76
Redhill Biopharma
RDHL
$3.95M
| $3.95M | $0.6500 | 0.51% |
|
77
China SXT Pharmaceuticals
SXTC
$3.38M
| $3.38M | $2.56 | 32.6% |
|
78
PRF Technologies Ltd
PRFX
$3.1M
| $3.1M | $0.8858 | 4.5% |
|
79
Shuttle Pharmaceuticals
SHPH
$2.03M
| $2.03M | $3.47 | 1.7% |
|
80
Akanda
AKAN
$1.7M
| $1.7M | $3.14 | 4.67% |
|
|
IMCC
81
IM Cannabis
IMCC
$1.06M
| $1.06M | $1.76 | 0.57% |
|
Drug Manufacturers - Specialty & Generic Stocks at a Glance
Specialty and generic drug manufacturers develop branded niche therapies, off-patent generics, and animal-health and cannabis products. Generics compete on price and manufacturing scale, while specialty brands carry pharma-like margins on smaller markets.
There are 81 Drug Manufacturers - Specialty & Generic industry stocks tracked by Wall St. Rank, worth a combined $335B.
The largest by market cap are Takeda Pharmaceutical (TAK) at $58.3B, Teva Pharmaceuticals (TEVA) at $42.9B and Haleon (HLN) at $40.3B.
Among institutional investors, Trulieve Cannabis Corp (TRLV) drew the most net new fund positions in Q2 2026: 121 funds opened new positions, taking total fund holders up 119 (1,983%) quarter-over-quarter.
- Combined market cap: $335B across 81 stocks.
- Largest constituent: Takeda Pharmaceutical (TAK), $58.3B market cap.
- Most net new fund positions in Q2 2026: Trulieve Cannabis Corp (TRLV), +119 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.